Core Viewpoint - A class action lawsuit has been filed against Integer Holdings Corporation and certain senior executives for securities fraud following a significant drop in stock price due to alleged violations of federal securities laws [1][3]. Company Overview - Integer Holdings Corporation specializes in designing and manufacturing cardiac rhythm management and cardiovascular products, including electrophysiology devices that diagnose and treat arrhythmias [4]. Allegations of Securities Fraud - The lawsuit claims that Integer misrepresented the demand and revenue for its electrophysiology products, which had reportedly fallen sharply, contradicting the company's public statements about sales growth and market position [4][5]. Stock Price Impact - On October 23, 2025, Integer revised its 2025 sales guidance downward to between $1.840 billion and $1.854 billion, significantly below analysts' expectations. The company also projected poor net sales growth of -2% to 2% and organic sales growth of 0% to 4% for 2026. This announcement led to a stock price drop of $35.22 per share, over 32%, from $109.11 to $73.89 [6].

Core Viewpoint - Baxter International, Inc. is facing a securities fraud class action lawsuit due to serious safety issues related to its Novum IQ Large Volume Pump, which has been linked to patient injuries and deaths, leading to a significant drop in stock price [1][4][5]. Group 1: Incident Overview - On April 7, 2025, a Missouri news outlet reported safety issues with Baxter's Novum LVP, claiming it was unsafe for patient treatment based on a whistleblower's information [2]. - Baxter issued warning letters on April 24 and July 14, 2025, regarding underinfusion and overinfusion risks, revealing 79 reports of serious injuries and two patient deaths associated with the device [3]. - The FDA classified the issues with Novum LVP as a Class I recall, indicating a severe risk of injury or death [3]. Group 2: Stock Impact - Following the announcement of a voluntary pause in shipments and installations of the Novum LVP on July 31, 2025, Baxter's stock price fell by $6.24, or 22.4%, closing at $21.61 per share [4]. Group 3: Lawsuit Details - The lawsuit alleges that Baxter made false or misleading statements regarding the safety and functionality of the Novum LVP, failing to disclose systemic defects and the risks associated with the device [5]. - It is claimed that Baxter was aware of multiple malfunctions and injuries but did not take adequate remedial measures, leading to a heightened risk of customers removing the devices from service [5].

Core Viewpoint - Inspire Medical Systems, Inc. is facing a class action lawsuit due to significant operational issues and a drastic reduction in earnings guidance following the announcement of delays in the launch of its new sleep apnea device, Inspire V [2][4]. Company Performance - On August 4, 2025, Inspire disclosed that the launch of Inspire V was delayed due to multiple issues, including inadequate training and onboarding of treatment centers, software update delays, and excess inventory leading to poor demand [2]. - The company reduced its 2025 earnings guidance by over 80%, from a range of $2.20 to $2.30 per share to a new range of $0.40 to $0.50 per share [2]. Stock Market Reaction - Following the announcement on August 5, 2025, Inspire's stock price dropped by $42.04, or 32.4%, closing at $87.91 per share, resulting in significant losses for investors [3]. Legal Allegations - The class action complaint alleges that during the class period, the defendants made materially false and misleading statements and failed to disclose adverse facts about the company's business and operations [4]. - Specific allegations include poor demand for Inspire V due to surplus inventory, incomplete training for treatment centers, and failure to ensure necessary IT systems and Medicare reimbursement were in place at launch [4].

Core Viewpoint - A class action securities lawsuit has been filed against DexCom, Inc. for alleged securities fraud affecting investors between January 8, 2024, and September 17, 2025 [1] Group 1: Allegations of Fraud - The lawsuit claims that DexCom made unauthorized material design changes to its glucose monitoring products, the G6 and G7, without FDA approval [2] - These design changes allegedly rendered the G6 and G7 less reliable, posing a material health risk to users who depend on these devices for accurate glucose readings [2] - The enhancements claimed for the G7, including its reliability, accuracy, and functionality, were reportedly overstated by the defendants [2] - The true scope and severity of the issues and health risks associated with the G7 devices were allegedly downplayed by the defendants [2] - The situation has subjected DexCom to increased regulatory scrutiny and potential legal, reputational, and financial harm [2] - Public statements made by the defendants were claimed to be materially false and misleading throughout the relevant period [2] Group 2: Legal Process and Participation - Investors who suffered losses in DexCom during the specified timeframe have until December 26, 2025, to request appointment as lead plaintiff [3] - Participation in the lawsuit does not require serving as a lead plaintiff, and class members may be entitled to compensation without any out-of-pocket costs [3] Group 3: Firm Background - Levi & Korsinsky has a history of securing hundreds of millions of dollars for shareholders and has extensive expertise in complex securities litigation [4] - The firm has been recognized in ISS Securities Class Action Services' Top 50 Report for seven consecutive years as one of the leading securities litigation firms in the U.S. [4]

NEW YORK, Dec. 12, 2025 (GLOBE NEWSWIRE) -- Levi & Korsinsky, LLP notifies investors in Inspire Medical Systems, Inc. ("Inspire Medical Systems, Inc." or the "Company") (NYSE: INSP) of a class action securities lawsuit. CLASS DEFINITION: The lawsuit seeks to recover losses on behalf of Inspire Medical Systems, Inc. investors who were adversely affected by alleged securities fraud between August 6, 2024 and August 4, 2025. Follow the link below to get more information and be contacted by a member of our team ...

Investment & Innovation - Fred Moll, cofounder of Intuitive Surgical (valued at $200 billion 十亿美元), has invested in approximately 15 companies focused on surgical robotics [1] - The invested companies are developing robots to enhance the accessibility of both complex and common surgeries [1]

Joining us to discuss is Craig Johnson, the chief market technician at Piper Sandler and Matt Orton is the chief market strategist at Raymond James. Welcome to you both. And Craig, I think you you've said like lean into the rotation, financials, industrials, the broadening out.Is that right. >> Absolutely, Kelly. That's exactly what we're seeing in this market.And it's it's been an interesting message as I've been conveying this to investors over the last couple days. This is a bull market, but it's a rotat ...

Core Viewpoint - A shareholder has filed a securities class action lawsuit against Integer Holdings Corporation, alleging misrepresentations regarding the company's market position and overstated demand for its electrophysiology devices during the class period from July 25, 2024, to October 22, 2025 [1][2]. Group 1 - The lawsuit claims that the defendants made false statements about Integer's standing in the growing electrophysiology market [2]. - The class action lawsuit is on behalf of investors who purchased or acquired Integer's common stock during the specified class period [1]. - Interested parties can file to serve as lead plaintiff by February 9, 2026, with no fees or expenses required from shareholders [3]. Group 2 - Bernstein Liebhard LLP, the law firm handling the case, has recovered over $3.5 billion for clients since 1993 and has a strong track record in class action litigation [4].

Key Takeaways ATRC treated its first patients with a dual-energy PFARFA platform, marking a key innovation step.ATRC pairs PFA with advanced RFA to speed procedures and give surgeons more flexible ablation options.ATRC's initial cases achieved complete box lesions in under 60 seconds with acute electrical isolation.AtriCure (ATRC) recently took a major step forward in surgical ablation innovation with the first patients successfully treated using its new dual-energy platform. The system uniquely pairs Pulse ...

Key Takeaways CeriBell gained FDA clearance for its continuous EEG-based delirium monitoring solution.The system delivers real-time EEG insights to cut clinical variability and aid earlier delirium detection.Tested on 225 adults, the algorithm builds on prior Breakthrough status and ties to a CMS NTAP bid.CeriBell Inc. (CBLL) recently announced that the FDA has given 510(k) clearance for its latest delirium monitoring solution, making it the one and only FDA-cleared solution for continuous tracking of delir ...